<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534753</url>
  </required_header>
  <id_info>
    <org_study_id>MGP-101</org_study_id>
    <nct_id>NCT02534753</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetics Study of Intravenous Ascorbic Acid</brief_title>
  <official_title>A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGuff Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGuff Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-dose study to evaluate the pharmacokinetics of intravenous Ascorbic
      Acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are:

        1. To evaluate the single-dose pharmacokinetics of AA administered intravenously (IV).

        2. To evaluate the safety and tolerability of AA administered intravenously.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Ascorbic Acid (µM) in plasma</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) grouped by body system</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in clinical laboratory and vital signs to discharge</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from pre-dose physical exam findings to discharge</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Single Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascor L 500® (Ascorbic Acid Injection, USP)</intervention_name>
    <description>A sterile, solution containing 500 mg ascorbic acid per mL</description>
    <arm_group_label>Single Group</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is between the ages of 18 and 45 years, inclusive.

          -  Has a body mass index (BMI) between 18 and 32 kg/m2.

          -  Of sound health and has the ability to understand the requirements of the study and is
             willing to comply with all study requirements and procedures.

        Exclusion Criteria:

          -  Participates in activities that would not allow accurate evaluation of the
             pharmacokinetics of Ascorbic Acid

          -  Medical or physical conditions that would not allow safe participation and/or accurate
             evaluation of the pharmacokinetics of Ascorbic Acid

          -  Has participated in an investigational drug study within the 30 days prior to CRU
             admission.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damon P Jones, BS/MBA</last_name>
    <role>Study Director</role>
    <affiliation>McGuff Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

